Human Pegivirus (HPgV) as an Immunomodulator in HIV Infection: Markers of Disease Progression and Therapeutic Perspectives
Viruses · 15.11.2026 · 18 (11) · 1268
DOI: 10.3390/v18111268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 15.11.2026. Verfasst von Arina A. Kiryakina und 5 weiteren Autor:innen. Die Arbeit nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Order of the Government of the Russian Federation.
Abstract (Originalsprache)
Human pegivirus 1 (HPgV-1) is a widespread RNA virus detected in lymphoid and other hematopoietic cells, although its principal cellular reservoir in vivo remains uncertain. In people living with HIV-1 (PLWH), persistent HPgV-1 viremia has been associated with higher CD4+ T-cell counts, lower HIV-1 viral loads, and improved clinical outcomes, although these associations are inconsistent across studies. This review summarizes epidemiological, clinical, and experimental data on the biology of HPgV-1 and HPgV-2, their interactions with HIV-1, HCV, and the host immune system, as well as the influence of antiretroviral therapy and viral genetic variability. The strongest mechanistic evidence concerns HPgV-1 and includes experimental inhibition of HIV-1 entry or replication by the E2, NS3, and NS5A proteins; modulation of chemokines and CCR5/CXCR4 coreceptors, TCR/IL-2/STAT5 signaling, and NK-cell functions; and associations with Fas/CD95 expression and interferon-dependent responses. Clinical associations may vary according to HPgV viremia status, anti-E2 seropositivity, ART exposure, and cohort characteristics, while data on HPgV-2 remain limited. The potential impact of HPgV on HIV persistence and proviral reservoirs is of particular interest, but direct evidence of changes in reservoir size or composition is lacking. HPgV should therefore be considered a model of natural virus-induced immunomodulation and a potential source of therapeutic molecules, although their clinical efficacy and long-term safety remain to be established.
Förderung
- Order of the Government of the Russian Federation
Zitieren
APA
Kiryakina, A. A., Boyko, M. A., Elfimov, K. A., Murzin, A. I., Agaphonov, A. P., & Gashnikova, N. M. (2026). Human Pegivirus (HPgV) as an Immunomodulator in HIV Infection: Markers of Disease Progression and Therapeutic Perspectives. Viruses, 18(11), 1268. https://doi.org/10.3390/v18111268
Vancouver
Kiryakina AA, Boyko MA, Elfimov KA, Murzin AI, Agaphonov AP, Gashnikova NM. Human Pegivirus (HPgV) as an Immunomodulator in HIV Infection: Markers of Disease Progression and Therapeutic Perspectives. Viruses. 2026;18(11):1268. doi:10.3390/v18111268
BibTeX
@article{Kiryakina2026,
author = {Kiryakina, Arina A. and Boyko, Margarita A. and Elfimov, Kirill A. and Murzin, Andrei I. and Agaphonov, Alexandr P. and Gashnikova, Natalya M.},
title = {Human Pegivirus (HPgV) as an Immunomodulator in HIV Infection: Markers of Disease Progression and Therapeutic Perspectives},
journal = {Viruses},
year = {2026},
volume = {18},
number = {11},
pages = {1268},
doi = {10.3390/v18111268}
}
EUVIMED